Jiménez-Navarro, ManuelMolero, EncarnaciónTeresa, Eduardo de2015-11-162015-11-162002-03-28Jiménez-Navarro M, Molero E, Teresa E de. Left ventricular assist device. N. Engl. J. Med.. 2002; 346(13):1023-5; author reply 1023-50028-4793http://hdl.handle.net/10668/2053To the Editor: The value of angiotensin-converting– enzyme (ACE) inhibitors, beta-blockers, and spironolactone has been well established by the results of numerous clinical trials. About 70 percent of the patients described by Rose et al. were treated with ACE inhibitors or angiotensin II–receptor antagonists; 35 to 40 percent received spironolactone, and only about 20 percent received beta-blockers. Thus, this population cannot have been considered to be optimally treated from the point of view of medical therapy.enInhibidores de la enzima convertidora de angiotensinaInsuficiencia cardíacaCorazón AuxiliarAntagonistas Adrenérgicos betaEspironolactonaMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors::Angiotensin-Converting Enzyme InhibitorsMedical Subject Headings::Diseases::Cardiovascular Diseases::Heart Diseases::Heart FailureMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Assisted Circulation::Heart-Assist DevicesMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Lactones::SpironolactoneMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Neurotransmitter Agents::Adrenergic Agents::Adrenergic Antagonists::Adrenergic beta-Antagonistsletter11924655open access1533-4406